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Abstract 
AIM: The purpose of the present research was to study the content of erythropoietin and hepcidin in serum in 
pregnant women with iron deficiency anaemia and anaemia of chronic inflammation. 
METHODS: The authors examined 98 pregnant women who were observed in LLP (Regional obstetric-
gynaecological centre) in Karaganda. The including criteria for pregnant women in the study was the informed 
consent of the woman to participate in the study. Exclusion criteria were oncological diseases, HIV-infection, 
tuberculosis, severe somatic pathology, mental illness, drug addiction. The design of the study was by the 
legislation of the Republic of Kazakhstan, international ethical norms and normative documents of research 
organisations, approved by the ethics committee of the Karaganda State Medical University. 
RESULTS: As a result of the study, it was determined that the content of erythropoietin and hepcidin in pregnant 
women with anemias of different genesis varies ambiguously. In the main group of pregnant women with IDA, the 
erythropoietin content rises, and the hepcidin level decreases. In pregnant women with ACI, on the contrary, the 
level of hepcidin increases, and in one subgroup it is significant. However, in pregnant women and with IDA and 
anemia of chronic inflammation, there is a subgroup of women in whom erythropoietin is either comparable with 
hepcidin, or their changes are of opposite nature. 
CONCLUSION: The authors concluded that the obtained data indicate ambiguous changes in the level of 
erythropoietin and hepcidin in pregnant women with anaemias of various origins. In all likelihood, there are still 
unaccounted factors affecting the content of these protein-regulators of iron metabolism, which require further 
definition and interpretation in anaemia of pregnant women. 
 
 
 
 
 
Introduction 
 
Anaemia of pregnant women continues to be 
one of the main problems of obstetrics and 
gynaecology. The multifactorial nature of the 
development of anaemia in pregnant women (AP), the 
complexity of pathogenesis creates problems for 
determining the criteria for diagnosing the aetiology of 
anaemia and, subsequently, for adequate therapeutic 
correction. Traditional anaemia biomarkers are not 
always sufficiently informative to determine the 
aetiology of anaemia in pregnant women. This 
significantly complicates the implementation of 
preventive or therapeutic interventions to correct the 
violation of iron metabolism. A convincing opinion was 
expressed that in some cases, the appointment of iron 
preparations to pregnant women with anaemia of 
chronic inflammation can induce oxidative stress and 
promote the growth of bacteria, thereby exacerbating 
the complications of pregnancy, i.e. anaemia of 
medium degree is a protective mechanism against 
bacterial and fungal pathogens [1] [2]. 
Currently, the main emphasis was made on 
the study of erythropoietin and hepcidin to deepen the 
understanding of the state of iron metabolism in 
particular and erythron in general in the body of 
pregnant women (including with AP). 
Erythropoietin is a hormone, synthesised in 
the kidneys and perisinusoidalliver cells (mainly in the 
embryonic and perinatal periods). It is a glycoprotein 
with a molecular weight of 34 kDa. The secretion of 
erythropoietin in the blood is regulated by the body 
oxygen regime [3]. Synthesis of erythropoietin has no 
humoral or neural regulation. The production of 
erythropoietin depends only on the oxygen content 
and is controlled by the feedback principle. 
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The main function of erythropoietin is the 
regulation of erythropoiesis [4]. The intensity of the 
formation of new erythrocytes in the bone marrow 
depends on the level of endogenous erythropoietin in 
the plasma. Inadequate to hypoxia levels, the 
development of own erythropoietin can lead to the 
occurrence of anaemia. Under normal conditions, in 
response to a decrease in oxygenation of tissues and 
cells, there is an increase in the synthesis of 
erythropoietin by the kidneys. The isolated hormone 
interacts in the bone marrow with specific receptors 
on the surface of the progenitor cells of erythrocytes, 
which stimulates their proliferation and differentiation 
and, as a result, increases the concentration of 
haemoglobin. 
Also, erythropoietin induces other effects, 
including increases systemic blood pressure, 
increases iron absorption by inhibiting hepcidin activity 
[5]. Erythropoietin also has a cytoprotective effect on 
the brain, kidney and heart cells by limiting apoptosis, 
oxidative stress, and has anti-inflammatory activity [6]. 
The erythropoietin concentration increases in 
2-4 times at the developing physiological anaemia of 
pregnant women [7]. According to Erdem et al., [8], a 
low concentration of haemoglobin and ferritin with an 
increase in serum erythropoietin content was noted in 
pregnant women with anaemia. A similar view that 
anaemia during pregnancy induces the secretion of 
erythropoietin in response to a low content of 
haemoglobin and ferritin is expressed in a later study 
of Ervasti M. et al., [9]. It should also be noted that 
studies have appeared on the use of erythropoietin as 
a therapeutic agent in anaemia of pregnant women 
[10]. 
At the moment about 20 regulatory molecules 
are known to control this complex process. Over the 
past few years, the role of hepcidin as a key regulator 
of iron metabolism has been actively discussed. 
Hepcidin, a peptide hormone consisting of 25 
amino acid residues, is synthesised in the liver. For 
the first time, hepcidin was detected in urine and 
described by S.N. Park et al., Later, this peptide was 
also isolated from the plasma. A distinctive feature of 
the hepcidin molecule is the presence in it of disulfide 
bonds between two neighbouring molecules of the 
amino acid cysteine, which can determine the high 
reactivity of the molecule. With the development of 
systemic infection, hepcidin rises more than 100 
times. However, as has been shown in recent years, 
the role of hepcidin is associated with clinical 
abnormalities in the parameters of iron metabolism, 
and some cases – with the development of anaemia. 
In addition to hepatocytes, hepcidin mRNA is 
also expressed in the cells of the heart, lungs and 
placenta. Hepcidin regulates the intestinal absorption 
of iron, iron release by macrophages and placental 
passage of iron. Also, this hormone inhibits the 
release of iron from cells by binding and enhancing 
the degradation of the protein-iron exporter ferroportin 
[11]. Hepcidin inhibits ferroportin, a specific carrier 
protein that carries iron to the interior of the cell, 
thereby impairing the absorption of iron in the small 
intestine. Another mechanism of action: hepcidin 
blocks the release of iron from macrophages, (locking) 
it inside the cell. Both these mechanisms lead to a 
violation of the homeostasis of iron, actually to iron 
deficiency and the development of anaemic 
syndrome, including in pregnant women. Analysis of 
literature data showed a limited number of studies 
about hepcidin in pregnant women. It was shown by 
Amat Bah et al. studies that the hepcidin 
concentration decreased by the 20
th
 week of 
gestation, while the iron stores in the body of pregnant 
women decreased by the 30
th
 gestation week [12]. 
The decrease in hepcidin level in pregnant women is 
suggested to be considered as a potential criterion for 
determining individual needs for intervention with iron 
preparations [13] [14]. At the same time, other data 
have been obtained that the concentration of hepcidin 
does not change depending on the trimester of 
pregnancy; there is also no correlation between 
hepcidin level and iron status [15]. 
Investigations of hepcidin level in pregnancy 
complications have been carried out. A study by M. 
Koenig et al., [16] showed an increase in serum 
hepcidin level in women with a high risk of pregnancy 
complications in comparison with healthy pregnant 
women. The hepcidin level was higher in pregnant 
women with pre-eclampsia than in the control group 
and positively correlated with the C-reactive protein. It 
is suggested that inflammation is a regulator of 
hepcidin production [11]. In inflammation, an increase 
of hepcidin level leads to a limitation of iron and a 
decrease in its availability for placental transfer. 
Consequently, analysis of literature data has 
shown a limited number of studies of erythropoietin 
and hepcidin anaemia in pregnant women. Because, 
according to some authors, erythropoietin and 
hepcidin are in reciprocal relationships, their joint 
determination has a great interest AP. 
In this regard, the purpose of our study was to 
study the content of erythropoietin and hepcidin in 
serum in pregnant women with iron deficiency 
anaemia and anaemia of chronic inflammation. 
 
 
Methods 
 
We examined 98 pregnant women who were 
observed in LLP (Regional obstetric-gynaecological 
centre) in Karaganda. The including criteria for 
pregnant women in the study was the informed 
consent of the woman to participate in the study. 
Exclusion criteria were oncological diseases, HIV-
infection, tuberculosis, severe somatic pathology, 
mental illness, drug addiction. The design of the study 
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was by the legislation of the Republic of Kazakhstan, 
international ethical norms and normative documents 
of research organisations, approved by the ethics 
committee of the Karaganda State Medical University. 
The object of the study was blood. The level 
of erythropoietin and hepcidin in serum was 
determined by the method of enzyme immunoassay. 
A set of Vector Best production (Russian Federation) 
was used to determine erythropoietin; a Cloud 
Cloncorp set was used to determine hepcidin 
(Houston, USA). Also in the blood of patients, the 
level of haemoglobin and serum iron was determined 
spectrophotometrically using Sysmex KX-21N and A-
15 analysers (BioSystems, Japan, Spain) 
Pregnant women were divided into 3 groups: 
22 women entered the group with the physiological 
course of pregnancy (1
st
group), 19 pregnant women 
with (iron deficiency anaemia) IDA (2
nd
 group), 57 
pregnant women with anaemia of chronic 
inflammation (ACI) (3
rd
group). 
Table 1: Characteristics of study groups 
Groups 
Average 
age (years) 
Average 
gestation 
(weeks) 
Second 
trimester 
(persons) 
Third 
trimester 
(persons) 
Parity: 
The first 
pregnancy 
Parity: 
The 
second 
pregnancy 
Parity: 
The third 
and more 
pregnancy 
Physiologicalpr
egnancy(22 
persons) 
33.13 31.81 2 20 10 6 6 
IDA 
(19 persons) 
30.38 32.77 1 18 3 6 10 
ACI 
(57 persons) 
29.51 36.11 2 55 12 29 16 
 
The diagnosis of iron deficiency anaemia was 
established on the basis of the lowered norm of the 
level of iron in the blood (less than 8 mmol/l), the 
diagnosis of ACI was established on the basis of 
anamnestic data on the presence of chronic 
pyelonephritis, arterial hypertension and edema 
during a previous or existing pregnancy, normal 
serum iron level, the presence of proteinuria and/or 
leukocyturia. 
The results were processed by statistical 
methods. 
 
 
Results 
 
After determining the hepcidin and 
erythropoietin content of, a multidirectional change in 
these parameters in the serum of pregnant women of 
the 2
nd
and 3
rd
groups was observed. By the obtained 
data, 2 subgroups were singled out within the 2
nd
 
group and 4 subgroups within the 3
rd
 group. The 
results of the study are presented in Table 1. It follows 
from the data in Table 1 that in pregnant women with 
IDA, a significant decrease in erythropoietin content is 
observed against a background of a decrease in 
haemoglobin and serum iron against a background of 
a clear trend towards an increase in hepcidin 
(subgroup 1). In pregnant women with IDA of 
subgroup 2 erythropoietin level exceeds control 
indices, whereas the content of hepcidin was not 
different from the control. 
In pregnant women with ACI of subgroup 1 
the erythropoietin and haemoglobin content is 
significantly lower control indices, while the hepcidin 
level shows a distinct tendency to increase. 
Table 2: The level of haemoglobin, erythropoietin, hepcidin and 
iron in the investigated groups 
Group Statistic value 
Haemoglobin, 
g/l 
Erythropoietin, 
miu/ml 
Hepcidin, 
ng/ml 
Iron, 
mmole/l 
Control,  
N=22 
Median 121.5 17.24 13.14 11.1 
Lower quartile 90 12.04 11.26 10.5 
Upper quartile 127.5 22.54 19.6 12.12 
IDA, 
subgroup 1, 
n=12 
Median 85.5* 7.20* 26.03 5.6* 
Lowerquartile 79.5 5.98 13.05 3.65 
Upperquartile 87.25 10.85 34.38 8.6 
IDA, 
subgroup2, 
n=7 
Median 88 23.19^ 12 8.11* 
Lowerquartile 85.5 18.47 9.65 6 
Upperquartile 125.5 24.88 22.34 9.5 
ACI 
Subgroup1, 
n=43 
Median 87* 9.30* 24.9 10.5 
Lowerquartile 82.5 5.61 13.78 8.9 
Upperquartile 89 11.57 35.56 10.85 
ACI 
Subgroup2, 
n=3 
Median 89 7.64* 199.62*! 11.25 
Lowerquartile 79.5 6.81 192.35 10.42 
Upperquartile 108 8.15 250.75 11.52 
ACI 
Subgroup3, 
n=7 
Median 124#; 25.23*#; 12; 10.75 
Lowerquartile 118.5 23.51 10 10.1 
Upperquartile 129 26.43 21.39 12.1 
ACI 
Subgroup4, 
n=4 
Median 83.5? 14.60:? 89.9*:? 10.05*: 
Lowerquartile 81 11.57 85.37 9.82 
Upperquartile 95.75 17.33 93.86 10.27 
 
*-reliability of differences with the control, p = 0.005; ^-reliability of differences in individuals 
with IDA between subgroups 1 and 3, p = 0.005; #-reliability of differences in persons with 
ACI between subgroups 1 and 4, p = 0.005; !!-reliability of differences in persons with ACI 
between subgroups 1 and 2+3, p = 0.005; ;-reliability of differences in individuals with ACI 
between clusters 2+3 and 4, p = 0.005; :-reliability of differences in individuals with ACI 
between clusters 2+3 and 5, p = 0.005; ?-the reliability of differences in individuals with 
ACI between clusters 4 and 5, p = 0.005. 
 
Against a background of a significant 
decrease in the level of erythropoietin, a sharp, 
significant increase in hepcidin level was registered in 
pregnant women with ACI, included in the subgroup 2. 
There was a significant increase in erythropoietin, 
while serum hepcidin concentration did not differ from 
control, in pregnant women with ACI, included in 
subgroup the 3. There was a significant decrease in 
erythropoietin level of relative to the subgroups 3 and 
2, with a significant increase in the content of hepcidin 
in pregnant women with ACI, included in the subgroup 
4. Also in patients in this group, the serum iron level 
was reliably reduced. It should be noted that 
multidirectional changes in the concentrations of 
erythropoietin and hepcidin in the blood serum were 
recorded in a small proportion of patients with ACI. 
 
 
Discussion 
 
It is known that an increased level of 
estrogen, accompanying pregnancy, causes a 
decrease in the production of erythropoietin. ACI is 
the result of inhibition of the synthesis of 
erythropoietin in the juxtaglomerular apparatus of the 
kidneys. Simultaneously, cytokines produced by 
macrophages in the presence of foci of chronic latent 
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inflammation, both in the organs of the female 
reproductive system and in other organs, in particular, 
the kidneys, contribute. An increase in the level of 
erythropoietin in the blood of pregnant women may 
reflect a high risk of preeclampsia [17]. 
As a result of the study, it was determined 
that the content of erythropoietin and hepcidin in 
pregnant women with anaemias of different genesis 
varies ambiguously. In the main group of pregnant 
women with IDA, the erythropoietin content rises, and 
the hepcidin level decreases. In pregnant women with 
ACI, on the contrary, the level of hepcidin increases, 
and in one subgroup it is significant. However, in 
pregnant women and with IDA and anaemia of chronic 
inflammation, there is a subgroup of women in whom 
erythropoietin is either comparable with hepcidin, or 
their changes are of opposite nature. 
Thus, our data indicate ambiguous changes in 
the level of erythropoietin and hepcidin in pregnant 
women with anaemias of various origins. In all 
likelihood, there are still unaccounted factors affecting 
the content of these protein-regulators of iron 
metabolism, which require further definition and 
interpretation in anaemia of pregnant women. 
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